Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs

February 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

NEW YORK--Physicians and patients contribute to undertreatment of both cancer-related and acute noncancer pain because of unwarranted fear of addiction to pain medications, according to an expert on pain management.

NEW YORK--Physicians and patients contribute to undertreatmentof both cancer-related and acute noncancer pain because of unwarrantedfear of addiction to pain medications, according to an experton pain management.

Despite well-documented evidence that patients are routinely undermedicated,ineffective pain control continues to compromise recovery andquality of life for cancer patients during and after treatment.In fact, said Seddon Savage, MD, director, Outpatient Pain Clinic,Dartmouth-Hitchcock Medical Center, fear of addiction is usuallyunfounded.

"The use of opioids in pain management is permeated withmythology, controversy, and many misunderstandings," shesaid at a media briefing on pain, sponsored by the American MedicalAssociation and Ortho-McNeil Pharmaceutical. She added that oversightby regulatory authorities further inhibits physicians in the useof these drugs.

Dr. Savage said that the fear of addiction is largely unwarranted,since individuals without a history of addictive disease rarelybecome addicted to medication for pain. "Most addicted individualshave a prior personal or family history of addiction of some type,"she said, adding that these individuals likely have a biogeneticpredisposition to addictive disease.

About 10% of the American population has an underlying addictivedisorder, and individuals with one substance dependency are atincreased risk for becoming addicted to another, she noted.

Dr. Savage defined addiction to prescription medication as drug-seekingbehavior characterized by continued use of a drug despite adverseconsequences; preoccupation with obtaining and using the drugwhile failing to comply with other aspects of treatment; and aninability to control the use of medications, including use ofthe drug in higher doses and with greater frequency than the physicianhas prescribed.

Patients with severe pain may engage in drug-seeking behavior,but it differs from addiction in that such behavior ceases assoon as adequate pain control is achieved, she said.

Opioid pain medication can be used safely, even in high dosesand over an extended period of time, if patients are carefullyselected and drug use is consistently monitored. Dr. Savage saidthat cancer-related pain can be managed most effectively withopioids, and there is ample evidence that opioids should be usedaggressively in cancer patients.

Government Scrutiny

In most states, physicians who prescribe opioid pain medicationare subject to oversight by government agencies and medical licensingboards.

"Doctors who prescribe opioids aggressively for pain areheavily scrutinized. Although this is often appropriate, it hasa negative impact on pain control," Dr. Savage said, pointingto cumbersome record-keeping requirements in some states thatcan cause the patient to become a burden to the physician.

Articles in this issue

FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
2 experts in this video
2 experts in this video
Related Content
Advertisement

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors

Russ Conroy
July 10th 2025
Article

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.


The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC

Roman Fabbricatore
July 10th 2025
Article

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Related Content
Advertisement

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

Roman Fabbricatore
July 10th 2025
Article

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors

Russ Conroy
July 10th 2025
Article

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.


The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Botensilimab/Balstilimab Elicits Sustained Efficacy in MSS Metastatic CRC

Roman Fabbricatore
July 10th 2025
Article

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.